These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19904250)

  • 1. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B.
    Chen WY; Chang WL; Tsai YC; Cheng HC; Lu CC; Sheu BS
    Am J Gastroenterol; 2010 May; 105(5):1046-52. PubMed ID: 19904250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP2C19 genotypes determine the efficacy of on-demand therapy of pantoprazole for reflux esophagitis as Los-Angeles grades C and D.
    Sheu BS; Cheng HC; Yeh YC; Chang WL
    J Gastroenterol Hepatol; 2012 Jan; 27(1):104-9. PubMed ID: 21777277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of body mass index on the application of on-demand therapy for Los Angeles grades A and B reflux esophagitis.
    Sheu BS; Cheng HC; Chang WL; Chen WY; Kao AW
    Am J Gastroenterol; 2007 Nov; 102(11):2387-94. PubMed ID: 17850409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2006; 74(3-4):145-54. PubMed ID: 17230024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse.
    Glatzel D; Abdel-Qader M; Gatz G; Pfaffenberger B
    Digestion; 2007; 75 Suppl 1():69-78. PubMed ID: 17489035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole.
    Sheu BS; Chang WL; Cheng HC; Kao AW; Lu CC
    Am J Gastroenterol; 2008 Sep; 103(9):2209-14. PubMed ID: 18702650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous proton pump inhibition utilization and prescribing patterns escalation: a comparison between early and current trends in use.
    Law JK; Andrews CN; Enns R
    Gastrointest Endosc; 2009 Jan; 69(1):3-9. PubMed ID: 18718583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
    Calleja JL; Suarez M; De Tejada AH; Navarro A;
    Dig Dis Sci; 2005 Mar; 50(3):432-9. PubMed ID: 15810621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral pantoprazole for erosive esophagitis: a placebo-controlled, randomized clinical trial. Pantoprazole US GERD Study Group.
    Richter JE; Bochenek W
    Am J Gastroenterol; 2000 Nov; 95(11):3071-80. PubMed ID: 11095320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group.
    Wurzer H; Schutze K; Bethke T; Fischer R; Luhmann R; Riesenhuber C
    Hepatogastroenterology; 1999; 46(27):1809-15. PubMed ID: 10430350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does BMI affect the clinical efficacy of proton pump inhibitor therapy in GERD? The case for rabeprazole.
    Pace F; Coudsy B; DeLemos B; Sun Y; Xiang J; LoCoco J; Casalini S; Li H; Pelosini I; Scarpignato C
    Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):845-51. PubMed ID: 21900784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole.
    Mönnikes H; Pfaffenberger B; Gatz G; Hein J; Bardhan KD
    Digestion; 2007; 75 Suppl 1():62-8. PubMed ID: 17489034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-demand proton pump inhibitory treatment in overweight/obese patients with gastroesophageal reflux disease: are there pharmacodynamic arguments for using higher doses?
    Bruley des Varannes S; Coudsy B; Waechter S; Delemos B; Xiang J; Lococo J; Ducrotté P
    Digestion; 2013; 88(1):56-63. PubMed ID: 23880545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results from a randomized, double-blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis.
    Baker R; Tsou VM; Tung J; Baker SS; Li H; Wang W; Rath N; Maguire MK; Comer GM
    Clin Pediatr (Phila); 2010 Sep; 49(9):852-65. PubMed ID: 20522615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study.
    Goh KL; Benamouzig R; Sander P; Schwan T;
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):205-11. PubMed ID: 17301646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of twice-daily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.
    Kinoshita Y; Hongo M;
    Am J Gastroenterol; 2012 Apr; 107(4):522-30. PubMed ID: 22433921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-demand therapy for Los Angeles grade A and B reflux esophagitis: esomeprazole versus omeprazole.
    Kao AW; Sheu BS; Sheu MJ; Chang YM; Huang SF; Chuang CH; Lai YL; Kao YH
    J Formos Med Assoc; 2003 Sep; 102(9):607-12. PubMed ID: 14625604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease.
    Cheong JH; Kim GH; Lee BE; Choi MK; Moon JY; Ryu DY; Kim DU; Song GA
    Scand J Gastroenterol; 2011 Jul; 46(7-8):789-96. PubMed ID: 21615222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.